Treatment of Primary Myelofibrosis When Platelet Count Is Below 50 × 10&sup9;/L

Patients with primary myelofibrosis who require treatment but have a platelet count below 50 × 10&sup9;/L represent a distinct clinical subgroup. Severe thrombocytopenia in this setting constrains agent selection and demands a carefully tailored approach.

Clinical scenario

Myelofibrosis requiring treatment in the context of a platelet count <50 × 10&sup9;/L (thrombocytopenic MF). This degree of thrombocytopenia is the defining feature of this protocol, and certain agents carry specific regulatory recognition for use in exactly this platelet range.

Treatment approach — partial overview

Management draws from several distinct therapeutic categories, including a hormonal agent, targeted kinase inhibitors with mandatory haematological monitoring, and immunomodulatory regimens. At least one agent in current use holds regulatory approval specifically for myelofibrosis patients in this platelet range. Specific sequencing, selection criteria, contraindications, and monitoring requirements are detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Thrombocytopenic MF with platelets <50×10&sup9;/L
Pacritinib is FDA-approved specifically for patients with MF and platelet counts <50 × 10&sup9;/L.
Danazol starting at 200mgs titrated to 600mgs
Low dose ruxolitinib with close monitoring of FBC
Pacritinib 200 mg twice daily if licensed
Momelotinib 200 mg daily if licensed in 1st line
IMIDS +/- steroids +/- danazol
It should not be used in patients with active bleeding and should be withheld for 7 days prior to any planned surgical intervention.

View source ↗